Desmopressin

Desmopressin (1-deamino-8-D-arginine vasopressin, or DDAVP) is a synthetic analog of the natural posterior pituitary hormone arginine vasopressin (antidiuretic hormone, ADH). Two key structural modifications — deamination at position 1 and substitution of L-arginine with D-arginine at position 8 — give desmopressin approximately 10 times the antidiuretic potency of native vasopressin while virtually eliminating its vasopressor (blood pressure-raising) activity. This selectivity for V2 receptors (antidiuretic) over V1 receptors (vasopressor) makes desmopressin clinically superior to native vasopressin for most therapeutic applications.

Desmopressin is the treatment of choice for central diabetes insipidus, a condition resulting from insufficient ADH production by the posterior pituitary, causing excessive dilute urine production and potentially dangerous dehydration. By activating V2 receptors in the renal collecting ducts, desmopressin increases water reabsorption and concentrates the urine, dramatically reducing urine output and restoring fluid balance.

Beyond its antidiuretic effects, desmopressin stimulates the release of von Willebrand factor (vWF) and Factor VIII from endothelial cells, making it valuable for the treatment of bleeding in patients with mild hemophilia A and type 1 von Willebrand disease. This hemostatic effect allows desmopressin to be used prophylactically before minor surgical procedures or therapeutically for acute bleeding episodes in these patients, potentially avoiding the need for plasma-derived clotting factor concentrates.

Desmopressin is also widely used for primary nocturnal enuresis (bedwetting) in children and nocturia in adults, where its antidiuretic effect reduces nighttime urine production. The drug is available in multiple formulations including intranasal, oral, sublingual, and injectable, providing flexibility for different clinical scenarios.